EUPRAXIA PHARMACEUTICALS INC.
About EUPRAXIA PHARMACEUTICALS INC.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$38.6M
- Total assets
- $86.2M
- Market cap
- $388.7M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $388.7M
- Shares outstanding
- 64.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 9, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $38.6M in FY2025.
- Trading 34% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review EUPRAXIA PHARMACEUTICALS INC..
Write a review
News about EUPRAXIA PHARMACEUTICALS INC.
News & sentiment via Polygon.io
